Actavis’ Global Hospital Business Unit, established in 2006 following the acquisition of Sindan in Romania, is comprised of a small team of commercial and technical specialists with extensive experience in the generic hospital market.
The Unit is responsible for the strategic and operational development of a world-class hospital channel business for Actavis in all-important markets worldwide.
Actavis currently markets a large number of successful products in Europe. These include well known brands such as Decubal and Reteplase, as well as established generics such as vancomycin and a wide range of cytotoxic medicines.
A solid footing in Europe
Actavis already markets over 50 hospital products, with a focus on oncology products and a growing range of anti-infectives, local anaesthetics and analgesics. More recently Actavis extended its portfolio through the acquisition of Floxapen from GSK, as well as Reteplase (Rapsylin) and Isotretenoin (Acitretin) from Roche.
Actavis’ exclusive rights agreement to distribute and sell the Deltaselect injectable range in Germany and other select countries came into effect in October 2007. This transaction has established Actavis as a major player in the German hospital market.
Actavis currently markets over 30 molecules from the Deltaselect portfolio in the German market and plans are in place to introduce up to eight complementary molecules over the coming year.
Work is also already underway to register and sell these products in a number of other countries.
Actavis has set its sights firmly on the hospital sector and currently has around 300 pending applications worldwide for injectable medicines. Furthermore, Actavis' ambitious pipeline comprises more than 60 new projects, developed both internally and through established relationships with other developers.
"Actavis is already renowned for fast access to high quality, affordable generics. We are excited and pleased to be extending our product range to hospitals throughout Europe. We look forward to being of service to hospital pharmacists over the coming years."
Robert Wessman, President & CEO